InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a Dutch biopharmaceutical company that develops long-acting injectable formulations for peptides, biologics, and small molecules using its proprietary SynBiosys biodegradable polymer platform, serving global pharma and biotech partners.
- Company typePrivate
- Founded2003
- HeadquartersGroningen, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What InnoCore Pharmaceuticals does
InnoCore Pharmaceuticals (legally Innocore Technologies B.V.) is a privately held biopharmaceutical drug delivery company founded in 2003 and headquartered in Groningen, Netherlands. The company develops long-acting injectable (LAI) formulations for peptides, biologics, oligonucleotides, and small molecules using its proprietary SynBiosys® multi-block copolymer matrix platform, which combines hydrophilic PEG-containing domains with hydrophobic crystalline domains to protect fragile APIs from degradation and enable tunable sustained release from days to 18 months. InnoCore offers three dosage form technologies — monodispersed microspheres, biodegradable implants extruded at low temperatures, and in-situ forming depots — supported by cGMP manufacturing capability, with the first SynBiosys-based product having received regulatory approval in 2013 and being commercially available in EU, Japan, and Asia.
InnoCore Pharmaceuticals firmographics
Firmographics- Name
- InnoCore Pharmaceuticals
- Legal name
- Innocore Technologies B.V.
- Website
- https://innocorepharma.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InnoCore Pharmaceuticals is a Dutch biopharmaceutical company that develops long-acting injectable formulations for peptides, biologics, and small molecules using its proprietary SynBiosys biodegradable polymer platform, serving global pharma and biotech partners.
- Ownership category
- akta.pro rank
InnoCore Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Drug Delivery Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule API Process Development & Route Scouting (HLAGAHAA)
- akta.pro secondary industries
- Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
Keywords
Where InnoCore Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Groningen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
InnoCore Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Contract Development Services: InnoCore generates revenue through contract development partnerships with pharmaceutical and biotech companies. The company provides formulation development, process optimization, analytical characterization, and manufacturing services for long-acting injectable drug products using its proprietary SynBiosys platform. Engagements span from early feasibility through clinical development to commercial technology transfer.
- Government and Foundation Grants: InnoCore receives grant funding from organizations including the Bill & Melinda Gates Foundation ($1.5M grant for contraceptive implant), European Just Transition Fund, and European Regional Development Fund. These grants support specific development programs and research initiatives.
- Technology Licensing: The company licenses its proprietary SynBiosys technology platform and related manufacturing processes to pharmaceutical partners for development and commercialization of long-acting injectable products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
InnoCore Pharmaceuticals product offering
Product offeringCore offering
InnoCore Pharmaceuticals is a B2B pharmaceutical development partner that formulates long-acting injectable (LAI) drug products using its proprietary SynBiosys® biodegradable polymer platform. The company provides contract formulation development, analytical characterization, process optimization, cGMP clinical manufacturing, and technology transfer services for peptides, biologics, oligonucleotides, and small molecules, with tunable sustained release from days to 18 months. InnoCore also licenses the SynBiosys platform and related manufacturing know-how to pharmaceutical partners for development and commercialization of LAI products.
Product overview
InnoCore Pharmaceuticals offers a proprietary polymeric drug delivery platform (SynBiosys®) combined with three specialized dosage form technologies—Microspheres, Implants, and In-Situ Forming Depots. Together these enable the development of long-acting injectable (LAI) formulations for peptides, biologics, oligonucleotides, small molecules, and new modalities, with tunable release from days to 18 months. The company also develops InGell™ polymer technology and provides end-to-end formulation development, analytical characterization, and cGMP manufacturing services.
Differentiator
Problem solved
Functional benefit
Brands
- SynBiosys®: Proprietary polymeric drug delivery platform enabling stable, scalable LAI formulations for peptides and biologics with tunable release kinetics.
- InGell™
- AndroSphere™
Products and services
- Pharmaceutical Contract Development Services End-to-end B2B formulation development, analytical characterization, process optimization, cGMP clinical manufacturing, and technology transfer services for long-acting injectable (LAI) drug products using the SynBiosys® platform, serving global pharma and biotech from feasibility through commercialization.
- SynBiosys® Biodegradable Polymer Drug Delivery Platform
Quantifiable outcome
- Extended peptide release to over 3 months with more than 90% activity retained
- +3 more outcomes
Companies that use InnoCore Pharmaceuticals
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
InnoCore Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
InnoCore Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- Bether Encapsulates and Solstice PharmaceuticalsminorBBubbleCaRD consortium partners for development of bioresorbable antibubbles for ultrasound-triggered drug delivery across the blood-brain barrier. Funded by European Union's European Regional Development Fund (ERDF), Dutch Ministry of Economic Affairs, and Groningen Municipality.
- OAinject Consortium (University of Twente and partners)minorConsortium under Dutch Research Council (NWO) Perspectief programme to develop new therapies for osteoarthritis. InnoCore contributes long-acting injectable formulations using bioresorbable polymeric drug delivery systems for intra-articular delivery of new biotech-derived therapeutics.
- DRIVE ConsortiumminorDiabetes-Reversing Implants for enhanced Viability and long-term Efficacy consortium. InnoCore contributed SynBiosys-based VEGF microspheres with continuous release of bioactive VEGF combined with islet encapsulation device for diabetes treatment. Research published in MDPI pharmaceutics journal.
- PolyVationcoreCollaboration for AndroSphere development program - a long-acting injectable dosage form of recombinant human chorionic gonadotropin (rhCG) for treatment of hypogonadotropic hypogonadism. InnoCore contributes SynBiosys extended release microsphere technology; PolyVation contributes formulation expertise. Funded by European Regional Development Fund.
- University of Groningen and UMCGminorConsortium partners in European Regional Development Fund project to develop biodegradable polymer-based microneedle array patch for influenza vaccines. Project leverages combined expertise of academic and industry partners.
- Merck KGaAcoreGlobal cooperation agreement for InnoCore's proprietary SynBiosys biodegradable polymer platform. Merck (operating as MilliporeSigma in US/Canada) provides global footprint to make SynBiosys technology more widely available. Collaboration supports customers with formulation, process development and manufacturing services for injectable sustained release drug products.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
InnoCore Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Corbion: Dutch biopolymers specialist producing PLA and PGA polymers used in medical and pharmaceutical applications including bioresorbable implants. Comparable polymer platform foundation targeting biomedical and pharmaceutical customers.
- Ashland: Global specialty ingredients company supplying pharmaceutical polymers and excipients used in controlled-release dosage forms. Comparable in providing polymer chemistry building blocks that enable sustained-release injectable formulations.
- Croda International: UK specialty chemicals company with pharmaceutical excipients business including polymers and lipid-based drug delivery systems. Comparable as a broad supplier of pharmaceutical formulation ingredients, including polymeric excipients used in parenteral delivery.
- Evonik: German specialty chemicals major with bioresorbable polymer franchise (RESOMER PLGA/PGA) used in long-acting injectables. Direct competitor in biodegradable polymer excipients and parenteral drug delivery, serving the same pharma/biotech customer base with greater scale and broader CDMO capabilities.
Direct peers
- Surmodics: US medical device and drug delivery company with proprietary polymer-based sustained-release technology. Comparable in developing polymer-based controlled-release platforms for pharmaceutical and medical applications, including parenteral delivery.
- Lubrizol Life Science (formerly Particle Sciences): Specialty CDMO offering drug delivery and contract development services for complex injectables including long-acting formulations. Highly comparable B2B service model focused on parenteral formulation development for pharma and biotech partners.
- Ascendia Pharmaceuticals: Specialty CDMO focused on long-acting injectable formulation and complex injectable drug delivery. Closely comparable B2B services model providing nano/micro-particle formulation development for pharma and biotech partners.
- Phosphorex: US-based specialty company specializing in microsphere and biomaterial particle technology for drug delivery. Closely comparable niche CDMO providing particle engineering services for sustained-release injectable formulations.
- Polyganics (Regenity Biosciences): Netherlands-based bioresorbable polymer company founded by overlapping academic and industry principals from the same Groningen ecosystem. Develops bioresorbable medical devices and drug delivery platforms using similar polymer chemistry expertise as InnoCore.
Regional players
- Symeres: Netherlands-based contract research organization offering drug discovery and development services including formulation support. Regional comparable operating in the Dutch life sciences ecosystem with overlap in pharma development services and similar talent pool.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
InnoCore Pharmaceuticals social profiles
Digital presenceInnoCore Pharmaceuticals compliance and trust
Trust signalCompliance3 records
InnoCore Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
InnoCore Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles11 records
InnoCore Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InnoCore Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InnoCore Pharmaceuticals
What does InnoCore Pharmaceuticals do?
InnoCore Pharmaceuticals is a B2B pharmaceutical development partner that formulates long-acting injectable (LAI) drug products using its proprietary SynBiosys® biodegradable polymer platform. The company provides contract formulation development, analytical characterization, process optimization, cGMP clinical manufacturing, and technology transfer services for peptides, biologics, oligonucleotides, and small molecules, with tunable sustained release from days to 18 months. InnoCore also licenses the SynBiosys platform and related manufacturing know-how to pharmaceutical partners for development and commercialization of LAI products.
Is InnoCore Pharmaceuticals a public or private company?
InnoCore Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was InnoCore Pharmaceuticals founded?
InnoCore Pharmaceuticals was founded in 2003. It employs 11 to 50 people.
Where is InnoCore Pharmaceuticals based?
InnoCore Pharmaceuticals is headquartered in Groningen, Netherlands, in the Europe region.
How does InnoCore Pharmaceuticals make money?
Three revenue lines are on record. Pharmaceutical Contract Development Services are the primary driver. The others are government and Foundation Grants and technology Licensing.
Who are InnoCore Pharmaceuticals's main competitors?
Broad incumbents on record are Corbion, Ashland, Croda International and Evonik. Direct peers are Surmodics, Lubrizol Life Science (formerly Particle Sciences), Ascendia Pharmaceuticals, Phosphorex and Polyganics (Regenity Biosciences). Symeres is listed as a regional player.
Does InnoCore Pharmaceuticals have an API?
No public API is recorded for InnoCore Pharmaceuticals.
What industry is InnoCore Pharmaceuticals in?
InnoCore Pharmaceuticals's product category is Pharmaceutical Drug Delivery Services. Its primary akta.pro industry code is HLAGAHAA, Small-Molecule API Process Development & Route Scouting, with a secondary code of HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services. Its NAICS code is 325412 and its SIC code is 2834.